Please assess the completion status of the following clinical trial:

Trial Title: Investigation of Non-CE Marked Intermittent Catheters.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male~* Minimum 18 years of age and with full legal capacity~* Daily intermittent catheterization for bladder management, with at least two catheters used on average pr. day, during the last 3 months~* Ability to self-catheterize~* Written informed consent, signed letter of authority and signed secrecy agreement given~Exclusion Criteria:~* Participation in any other clinical study during this investigation~* Symptoms of urinary tract infection as judged by the investigator~* Any know allergies towards ingredients in the products~* Relevant medical history that would prevent the subject from participation in the investigation (investigators judgement)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intermittent catheter; SpeediCath® Standard male (Type: ACTIVE_COMPARATOR): Participants underwent two catheterizations with standard of care intermittent catheter: The first was performed by a trained nurse, the second by the participant later the same day.
- New intermittent catheter Variant 1 for males (Type: EXPERIMENTAL): Participants underwent two catheterizations with the new intermittent catheter Variant 1 for males: The first was performed by a trained nurse, the second by the participant later the same day.
- New intermittent catheter Variant 2 for males (Type: EXPERIMENTAL): Participants underwent two catheterizations with the new intermittent catheter Variant 2 for males: The first was performed by a trained nurse, the second by the participant later the same day.

Based on this trial design, predict the completion outcome and termination type (if applicable).